Oncology
David Johnson, MD
R. Ellwood Jones Distinguished Professor of Internal Medicine, University of Texas Southwestern Medical School
Dr. David H. Johnson is a Professor of Internal Medicine and a leading thoracic oncologist at UT Southwestern Medical Center in Dallas. His career has focused on developing novel treatments for lung cancer, including contributing significantly to the clinical development of paclitaxel (Taxol), bevacizumab (Avastin), and erlotinib (Tarceva)—all now FDA-approved for lung cancer treatment. He also played a key role in the development of G-CSF for neutropenia management. As a Fellow of the American
50+
Years in Practice
Credentials
Board Certifications
- Internal Medicine (American Board of Internal Medicine)
- Medical Oncology (American Board of Internal Medicine)
Education & Training
- Medical College of Georgia at Augusta University — M.D., Class of 1976
- Bassett Medical Center — Internship, Internal Medicine, 1976–1977
- USA Health — Residency, Internal Medicine, 1977–1979
- Vanderbilt University Medical Center — Fellowship, Hematology and Medical Oncology, 1981–1983
Peer Recognition
- Giants of Cancer Care — Giants of Cancer Care Award
2019
Clinical Focus
Subspecialties
Conditions & Treatments
Practice Details
Hospital Affiliations
- UT Southwestern Medical Center
Languages
English
Experience
50+ years in practice